XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Revenue REVENUEThe Company develops, manufactures and sells devices designed primarily for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and blocking pain by temporarily ablating peripheral nerves. These devices are marketed to a broad base of medical centers globally. The Company recognizes revenue when control of promised goods is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.
United States revenue by product type is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Open ablation $21,569$17,893$62,613$54,835
Minimally invasive ablation 10,0779,99028,84628,077
Pain management10,5106,25328,73415,860
Total ablation$42,156$34,136$120,193$98,772
Appendage management27,62023,40183,12069,144
Total United States$69,776$57,537$203,313$167,916
International revenue by product type is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2022202120222021
Open ablation $6,680$6,690$19,385$16,650
Minimally invasive ablation 1,4451,8494,2494,698
Pain management1211137522
Total ablation$8,246$8,550$24,009$21,370
Appendage management5,2244,37315,02911,825
Total International $13,470$12,923$39,038$33,195
Revenue attributed to customer geographic locations is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
United States$69,776$57,537$203,313$167,916
Europe7,2967,77022,31620,551
Asia5,5184,73415,00811,695
Other International6564191,714949
Total International13,47012,92339,03833,195
Total Revenue$83,246$70,460$242,351$201,111